Radiodermatitis Market Size

Global Radiodermatitis Market size was valued at USD 452.36 million in 2023 and is poised to grow from USD 470.91 million in 2024 to USD 649.44 million by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032). 

The demand for radiodermatitis treatment products is more critical than ever before due to the urgency in addressing this negative consequence. Radiodermatitis, which includes erythema, dry desquamation, and moist desquamation, affects a substantial 95% of cancer patients undergoing radiation therapy. Notably, 85-95% of breast cancer patients receiving radiotherapy also experience varying degrees of radiodermatitis.

The COVID-19 pandemic initially disrupted the radiodermatitis market, particularly in the radiation oncology departments, as healthcare institutions prioritized COVID-19 patients. This led to a decline in weekly radiation sessions in 2020 compared to the same months in 2019. However, with the easing of lockdowns and restrictions in various regions and the implementation of safe cancer treatment measures by cancer institutes, growth opportunities have emerged for the market in the post-COVID-19 period.

Furthermore, the increasing prevalence of diabetes and obesity has contributed to the rising cases of cancer. The Centers for Disease Control estimates that there were 34.2 million cases of diabetes worldwide in 2018, and this number is expected to reach 1.2 billion by 2030. As a result, a larger population of patients is at higher risk of developing cancer, and their co-morbid conditions make them more susceptible to radiation-induced skin damage. This trend is anticipated to drive the market's growth during the forecast period.

US Radiodermatitis Market is poised to grow at a sustainable CAGR for the next forecast year.